Population Qualitative Data

Population age groups

Paediatric Population (< 18 years)
Adults (18 to < 46 years)

Estimated percentage of the population covered by the data source in the catchment area

In France, early drug access before marketing authorization is granted by the French National Agency for the Safety of Medicines and Health Products (ANSM) in case on unmet need, positive benefit/risk balance of preliminary data and no access within clinical trials. All anticancer prescriptions approved by the ANSM from 01/01/2020 to 31/12/2021 for patients < 18 years-old have been analyzed. In the 2020-2021 period, 28 different therapies were prescribed to 188 patients in a French Society of Pediatric Oncology (SFCE) center. Of them, 14 patients never received the prescribed drug, mainly due to early death. 107 of 174 (61%) eligible patients from 21 SFCE centers were included in the SACHA study (56% in 2020 and 67% in 2021)
Population

Population size

500

Active population size

300

Population by age group

Age groupPopulation sizeActive population size
Paediatric Population (< 18 years)
450
270
Adults (18 to < 46 years)
50
30
Median observation time

Median time (years) between first and last available records for unique individuals

1.00

Median time (years) between first and last available records for unique active individuals (alive and currently registered)

2.00